Tempus AI, Inc. has launched an open-source digital pathology consortium alongside Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center [1].

This initiative seeks to democratize high-level diagnostic tools, potentially accelerating the development of precision medicine by providing the broader research and clinical communities with open access to digital pathology resources [2].

The consortium, known as digital pathology IMS Open-Source, involves founding partners based in New Haven, Connecticut, and New York, New York [2]. By sharing these tools, the partners intend to lower the barriers for institutions that lack the proprietary infrastructure to develop such advanced AI-driven pathology systems.

Market reaction to the announcement was positive. Tempus AI share price jumped 10 percent [3], eventually closing at $52.56 per share [3].

The collaboration focuses on the intersection of artificial intelligence and tissue analysis. Digital pathology allows for the conversion of glass slides into digital images, which can then be analyzed by machine learning algorithms to identify patterns in cancer cells and other diseases more accurately than manual review.

Tempus AI reported the launch of the consortium on June 3, 2024 [1]. The company and its partners are positioning the project as a way to standardize how digital pathology data is handled across different healthcare systems, a move that could streamline multi-institutional research studies.

While the project is open-source, the involvement of major centers like Memorial Sloan Kettering and Yale New Haven Hospital provides the consortium with a massive amount of clinical data and expertise to refine the tools before they are released to the public [2].

“Tempus AI share price jumped 10 percent”

The shift toward open-source digital pathology represents a strategic move to standardize AI diagnostics across the US healthcare system. By removing proprietary silos, Tempus AI and its partners are attempting to create a common technical language for tissue analysis, which may accelerate FDA approvals for new AI diagnostic tools and reduce the cost of precision medicine for smaller hospitals.